Ovarian Cancer | Clinical

Long-Term SOLO-1 Data Solidify Use of Maintenance Olaparib in BRCA1/2+ Ovarian Cancer

May 08, 2021

In an interview with Targeted Oncology, William H. Bradley, MD, discussed the results of the SOLO-1 trial of olaparib as a maintenance therapy for patients with ovarian cancer with a BRCA1/2 mutation, and other developments in the ovarian cancer field.

Future Directions in Ovarian Cancer

April 27, 2021

A leader in gynecologic oncology, Chirag Shah, MD, MPH, provides insight into the future of ovarian cancer by discussing the potential for immunotherapy, TP53 inhibition, and novel therapeutics on the horizon.

Molecular Testing in Ovarian Cancer

April 27, 2021

Key opinion leader in obstetrics and gynecology Chirag Shah, MD, MPH, discusses best practices for molecular testing and genetic counseling for patients with newly diagnosed or relapsed ovarian cancer.